The CR rate of intravesical OM after 3 months of treatment of 45 patients with BCGu NMIBC CIS was 40% in a phase 2 trial [37, 38], suggesting that the CR rate of OM after 3 months is lower than that of ALT-803 (78%) and pembrolizumab (56%). The gene discussed is GPT; the disease is in situ carcinoma.